Please assess the completion status of the following clinical trial:

Trial Title: Simultaneous TransPRK and Corneal Collagen Cross-Linking

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with progressive stage II or III keratoconus~* CDVA \< 0.00 logMAR or subjective problems with spectacle corrected visual quality (ghost images or light scatter symptoms)~Exclusion Criteria:~* Active ocular surface disease~* Minimum corneal thickness \<390µm (leaving 325µm residual stromal thickness after transPTK - in line with minimum thickness recommendations for the study CXL protocol)~* Vulnerable groups (patients whose capacity for giving informed consent to participate in the trial may be impaired)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- TransPRKCXL (Type: EXPERIMENTAL): Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
- CXL only (Type: ACTIVE_COMPARATOR): Corneal collagen cross-linking (CXL) using the same protocol without transepithelial photorefractive keratectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).